Hispanics/Latinos with non-small cell lung cancer have higher overall survival rates

Analysis of non-small cell lung cancer (NSCLC) patient records in the California Cancer Registry (CCR) database during the 20-year period of 1988-2008 indicates that Hispanics/Latinos with NSCLC have a higher overall survival compared to non-Hispanic white patients, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC), and The University of Chicago.

This study evaluated the records of 14,829 Hispanic patients from the CCR from 1988-2008. Foreign-born Hispanics had a 14 percent decreased risk for death compared to U.S.-born Hispanic patients, including individual patient factors and clinical factors. Adjustments for neighborhood factors, specifically socioeconomic status and ethnicity, slightly moderated the significant decrease in death risk among foreign-born Hispanics. The data also indicates that foreign-born Hispanics who lived in the least U.S.-assimilated neighborhoods had the better overall survival.

"The results of this study confirm the 'Hispanic paradox' of improved survival rates for Hispanic/Latino NSCLC patients compared to non-Hispanic white patients, despite lower socio-economic status," said lead author Manali Patel, MD, a post-doctoral fellow in the hematology/oncology department at Stanford University in Stanford, Calif. "Social and neighborhood factors, in addition to being foreign-born, appear to be positive contributing factors to incidence and survival that need further study."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer